Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Fresh from the biotech pipeline—2015

Nature Biotechnology volume 34, pages 129–132 (2016)Cite this article

Subjects

Novel drug approvals in the United States surpassed even 2014's unprecedented totals. The broad trends are familiar but, as Chris Morrison reports, 2015 had its share of pioneering achievements.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: FDA new molecular entities and biologic license approvals 1998–2015.

Author information

Authors and Affiliations

  1. Yardley, Pennsylvania

    Chris Morrison

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C. Fresh from the biotech pipeline—2015. Nat Biotechnol 34, 129–132 (2016). https://doi.org/10.1038/nbt.3472

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3472

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research